- Home
- CIFR vs CORT Comparison
CIFR vs CORT Comparison
Compare CIFR & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIFR | CORT |
|---|---|---|
| Founded | 2021 | 1998 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 3.7B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | CIFR | CORT |
|---|---|---|
| Price | $14.36 | $33.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $24.45 | ★ $105.20 |
| AVG Volume (30 Days) | ★ 24.0M | 1.7M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $39.59 | $29.97 |
| Revenue Next Year | $192.90 | $30.25 |
| P/E Ratio | ★ N/A | $41.48 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $1.86 | $28.66 |
| 52 Week High | $25.52 | $117.33 |
Technical Indicators
Market Signals| Indicator | CIFR | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 34.03 |
| Support Level | $13.84 | $33.53 |
| Resistance Level | $17.83 | $41.92 |
| Average True Range (ATR) | 1.39 | 2.45 |
| MACD | -0.15 | 0.25 |
| Stochastic Oscillator | 22.42 | 44.47 |
Price Performance
Historical ComparisonAbout CIFR Cipher Mining Inc.
Cipher Digital Inc is focused on high-performance computing (HPC) data center development and operations. It is engaged in developing and operating data centers designed for HPC workloads. Its operations include managing power assets and capital allocation in response to market conditions and demand for AI-related computing capacity.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.